BioSpace News Archive

Alnylam Pharmaceuticals, Inc. announced updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy.

COMPASS Pathways plc announced that positive data from an open-label phase 2 clinical trial of investigational COMP360 psilocybin in addition to daily selective serotonin reuptake inhibitors in treatment-resistant depression has been published online in the peer reviewed Nature journal, Neuropsychopharmacology.

Rhythm Pharmaceuticals, Inc. announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 1, 2023 to report its second quarter 2023 financial results and provide a corporate update.

Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that it will release financial results for its 2023 second quarter on Thursday, August 10, 2023 before the open of the U.S. financial markets.

Ondine Biomedical was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association in Tampere, Finland for demonstrating exceptional perseverance and clinical acumen.

Bio-Path Holdings, Inc. announced completion of the first dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1001-A in patients with solid tumors, including ovarian, endometrial, pancreatic and breast cancer.

Gritstone bio, Inc. today announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase an aggregate of 30,700 shares of its common stock with an exercise price of $2.02, which is equal to the closing price of Gritstone’s common stock on July 10, 2023.

Acumen Pharmaceuticals, Inc. will hold a conference call today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD.

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN) presented preclinical data further supporting the potential therapeutic advantage of lead candidate for AD, PMN310, a humanized IgG1 antibody directed toward toxic amyloid-beta oligomers (AβO).

Pardes Biosciences, Inc. announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company’s net cash at closing.